BVS
Bioventus Inc.
NASDAQ · Healthcare · Medical - Devices · US
$13.49
+1.43%Year over year
Reported trailing growth
- Revenue
- +3.1%
- EBITDA
- +22.9%
- EBIT
- +73.4%
- EPS
- —
- Free cash flow
- +176.5%
- Operating cash flow
- +167.3%
Forward estimates
Based on analyst estimates
- Revenue
- +8.6%
- EBITDA
- +19.8%
- EPS
- +5.2%
Three-year CAGR
- Revenue
- +3.5%
- EBITDA
- +152.9%
- EBIT
- +588.7%
- Net income
- +167.8%
- EPS
- +165.4%
- Free cash flow
- +199.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026